We invest to cure disease
Join our portfolio of founders seeking new cures
Smarter investments, greater impact
At Vibe Bio, we believe that groundbreaking cures shouldn’t be sidelined due to funding gaps or analytical limitations. Our venture fund is dedicated to empowering visionary founders developing platform technologies and therapeutics, especially those targeting rare or overlooked diseases.
Just as we empower our biopharma partners to make smarter BD and in-licensing decisions, we also apply VibeOne’s AI capabilities to guide, validate, and accelerate the success of our own investment portfolio.
Looking to raise? Let’s connect.
Seeking ambitious founders
We invest in exceptional founders developing high-potential therapies – regardless of modality o disease area. If you’re building something bold, let’s talk.
Gain an edge with AI
Our AI platform goes beyond due diligence. We share insights with our portfolio teams – from risk analysis to competitive benchmarking – to help them plan, be smarter, and move faster.
AI-enhanced
Utilizing our proprietary AI platform, VibeOne, we conduct rigorous due diligence to assess risk, benchmark against competitors, and plan strategically.
“The spirit of collaboration began before the investment.
Even during diligence, a mantra of ‘What can we do to help?’ has been evident from the Vibe Bio team.”
Evan Sussman, CEO and Co-founder, GranataBio
Our portfolio
Explore our portfolio of breakthrough biotech companies, vetted and backed by Vibe Bio.
Eigen Therapeutics
Eigen is pioneering a new class of “priming therapies” that unlock the full potential of targeted cancer treatments such as ADCs and radiopharmaceuticals. These small molecule primers selectively amplify therapeutic targets in tumor cells, dramatically improving the therapeutic window and expanding the addressable patient population for these modalities.
Although clinical proof-of-concept for priming has emerged from existing combination therapies, these successes have been products of serendipity rather than systematic discovery. Eigen is the first company to build a dedicated platform to systematically discover priming therapies.
Learn more about Eigen Therapeutic’s work.
Granata Bio
Granata Bio is boldly shaping the future of reproductive health by reimagining what’s possible to help build families. Founded in 2018, the company is dedicated to acquiring, developing, and accelerating fertility treatments that expand therapeutic choices and enhance access. Their fertility experts, strategic partnerships, and powerhouse portfolio aim to transform what’s possible on the path to parenthood.
Granata Bio grew its own family in 2025, expanding to include Oviva Therapeutics, Inc., a wholly owned subsidiary developing first-in-class therapeutics aimed at preserving ovarian function and extending reproductive longevity in women.
For more information, visit www.granata.bio and LinkedIn.
Cellular Intelligence
Cellular Intelligence (CI) is an AI-native TechBio company and clinical-stage biotech building a universal foundation model of cell signaling to understand, predict, and ultimately control cellular behavior, transforming biology from trial-and-error into an engineering discipline. We take a full-stack approach, generating perturbation data at over 1,000x the efficiency of conventional methods, capturing millions of time-resolved treatment combinations per experiment, and training large-scale models that generalize across contexts to enable rational protocol design for regenerative medicine, context-specific drug effect prediction, and systematic disease modeling.
CI founding team includes repeat AI entrepreneur Dr. Micha Breakstone (Chorus.ai, acquired for $575M), the Head of the Fundamental AI Group at MIT, and four professors from Harvard Medical School and the University of Washington, including the Chair of Genetics at Harvard, collectively holding five National Academy memberships. Based in Boston, CI has raised over $60M to date from Khosla Ventures, CZI, SciFi VC, and AMD Ventures, and is rapidly scaling its world-class team.
For more information, visit www.cellularintelligence.com and LinkedIn.
Supporting founders beyond capital
Our commitment extends beyond funding. We partner closely with our portfolio companies, offering:
Network Access: Connecting founders with a community of scientists, investors, and industry experts.
Strategic Insights: Leveraging AI-driven analyses to inform development pathways and identify opportunities.
Operational Support: Assisting with planning, regulatory strategies, and market positioning.
Funding with purpose: Your questions answered
How can potential partners collaborate with Vibe Bio?
Our due diligence team considers an array of variables in order to make a decision based on scientific merit and clinical opportunity. Our mission to find every cure for every community empowers us to invest in a variety of therapeutic areas.
Can I invest in the companies that Vibe Bio helps to finance? If so, how?
Yes, you can! Get in touch to learn more about investing opportunities.
How can I get funding for my biotech company?
If you are a founder-led, early-stage biotech looking to create an impact to find cure, reach out to us so we can learn about your promising project, upcoming milestones, and your path to the next crucial stage for your organization.
How does Vibe Bio diligence projects?
Our team performs thorough analysis of the scientific and business data in order to choose the best options for our portfolio. To help us make better, more accurate, and faster decisions, we use VibeOne for AI-driven assessment of drug program potential.
Join our mission
Vibe Bio uses AI-driven insights to inform investment decisions, improve real-world outcomes, and benchmark against industry standards. Learn how you can join us.